• David Ávila-Castro, Guadalupe Ortiz-Torres, Berenice Sánchez-Jara, Teresita Valle-Cárdenas, Efraín Aquino-Fernández, Ana I González-Ávila, and Abraham Majluf-Cruz.
• Instituto Mexicano del Seguro Social, Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Ciudad de México, México.
• Gac Med Mex. 2020 Jan 1; 156 (4): 344-353.

AbstractSARS-CoV-2 infection (COVID-19) has become a pandemic with a high case fatality rate that mainly affects adults. Most severely ill adult patients develop a coagulopathy that was not described until recently, and which is currently considered a main cause of death. Everything indicates that a similar phenomenon also occurs in children with COVID-19. Anticoagulant treatment has become one of the therapeutic foundations for this infection; however, its implementation in children can be difficult since, until recently, it was not considered in the pediatric population. Evidence regarding the use of anticoagulants in COVID-19 is rapidly generated, changes constantly, it is often difficult to interpret, and can be contradictory. After an extensive review of the published literature, a proposal was generated that offers suggestions for anticoagulant treatment, considering available resources in Mexico.Copyright: © 2020 Permanyer.

30 keywords...

hide…